APA (7th ed.) Citation

H, W., Y, J., S, K., W, K., F, Z., R, M., . . . R, K. (2026). Pharmacological targeting of the NLRP3 LRR domain with isothiazolinones overcomes CRID3-resistant inflammation. EMBO molecular medicine, 18(6), 2124. https://doi.org/10.1038/s44321-026-00425-5

Chicago Style (17th ed.) Citation

H, Woo, et al. "Pharmacological Targeting of the NLRP3 LRR Domain with Isothiazolinones Overcomes CRID3-resistant Inflammation." EMBO Molecular Medicine 18, no. 6 (2026): 2124. https://doi.org/10.1038/s44321-026-00425-5.

MLA (9th ed.) Citation

H, Woo, et al. "Pharmacological Targeting of the NLRP3 LRR Domain with Isothiazolinones Overcomes CRID3-resistant Inflammation." EMBO Molecular Medicine, vol. 18, no. 6, 2026, p. 2124, https://doi.org/10.1038/s44321-026-00425-5.